Literature DB >> 27450555

Bromodomain 4: a cellular Swiss army knife.

Ballachanda N Devaiah1, Anne Gegonne1, Dinah S Singer2.   

Abstract

Bromodomain protein 4 (BRD4) is a transcriptional and epigenetic regulator that plays a pivotal role in cancer and inflammatory diseases. BRD4 binds and stays associated with chromatin during mitosis, bookmarking early G1 genes and reactivating transcription after mitotic silencing. BRD4 plays an important role in transcription, both as a passive scaffold via its recruitment of vital transcription factors and as an active kinase that phosphorylates RNA polymerase II, directly and indirectly regulating transcription. Through its HAT activity, BRD4 contributes to the maintenance of chromatin structure and nucleosome clearance. This review summarizes the known functions of BRD4 and proposes a model in which BRD4 actively coordinates chromatin structure and transcription. © Society for Leukocyte Biology.

Entities:  

Keywords:  BRD4; Pol II; acetyltransferase; kinase; nucleosome eviction

Mesh：

Substances：

Year:  2016        PMID： 27450555      PMCID： PMC5014741          DOI： 10.1189/jlb.2RI0616-250R

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN： 0741-5400            Impact factor:   4.962


  69 in total

1.  A bromodomain protein, MCAP, associates with mitotic chromosomes and affects G(2)-to-M transition.

Authors:  A Dey; J Ellenberg; A Farina; A E Coleman; T Maruyama; S Sciortino; J Lippincott-Schwartz; K Ozato
Journal:  Mol Cell Biol       Date:  2000-09       Impact factor: 4.272

2.  Brd4 bridges the transcriptional regulators, Aire and P-TEFb, to promote elongation of peripheral-tissue antigen transcripts in thymic stromal cells.

Authors:  Hideyuki Yoshida; Kushagra Bansal; Uwe Schaefer; Trevor Chapman; Inmaculada Rioja; Irina Proekt; Mark S Anderson; Rab K Prinjha; Alexander Tarakhovsky; Christophe Benoist; Diane Mathis
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-27       Impact factor: 11.205

3.  RNA Polymerase II Regulates Topoisomerase 1 Activity to Favor Efficient Transcription.

Authors:  Laura Baranello; Damian Wojtowicz; Kairong Cui; Ballachanda N Devaiah; Hye-Jung Chung; Ka Yim Chan-Salis; Rajarshi Guha; Kelli Wilson; Xiaohu Zhang; Hongliang Zhang; Jason Piotrowski; Craig J Thomas; Dinah S Singer; B Franklin Pugh; Yves Pommier; Teresa M Przytycka; Fedor Kouzine; Brian A Lewis; Keji Zhao; David Levens
Journal:  Cell       Date:  2016-04-07       Impact factor: 41.582

4.  Selective inhibition of tumor oncogenes by disruption of super-enhancers.

Authors:  Jakob Lovén; Heather A Hoke; Charles Y Lin; Ashley Lau; David A Orlando; Christopher R Vakoc; James E Bradner; Tong Ihn Lee; Richard A Young
Journal:  Cell       Date:  2013-04-11       Impact factor: 41.582

5.  Bromodomain 4 activation predicts breast cancer survival.

Authors:  Nigel P S Crawford; Jude Alsarraj; Luanne Lukes; Renard C Walker; Jennifer S Officewala; Howard H Yang; Maxwell P Lee; Keiko Ozato; Kent W Hunter
Journal:  Proc Natl Acad Sci U S A       Date:  2008-04-21       Impact factor: 11.205

6.  BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma.

Authors:  Christopher A French; Isao Miyoshi; Ichiro Kubonishi; Holcombe E Grier; Antonio R Perez-Atayde; Jonathan A Fletcher
Journal:  Cancer Res       Date:  2003-01-15       Impact factor: 12.701

7.  Inhibition of BET bromodomain targets genetically diverse glioblastoma.

Authors:  Zhixiang Cheng; Yuanying Gong; Yufang Ma; Kaihua Lu; Xiang Lu; Larry A Pierce; Reid C Thompson; Susanne Muller; Stefan Knapp; Jialiang Wang
Journal:  Clin Cancer Res       Date:  2013-02-12       Impact factor: 12.531

8.  Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia.

Authors:  Mark A Dawson; Rab K Prinjha; Antje Dittmann; George Giotopoulos; Marcus Bantscheff; Wai-In Chan; Samuel C Robson; Chun-wa Chung; Carsten Hopf; Mikhail M Savitski; Carola Huthmacher; Emma Gudgin; Dave Lugo; Soren Beinke; Trevor D Chapman; Emma J Roberts; Peter E Soden; Kurt R Auger; Olivier Mirguet; Konstanze Doehner; Ruud Delwel; Alan K Burnett; Phillip Jeffrey; Gerard Drewes; Kevin Lee; Brian J P Huntly; Tony Kouzarides
Journal:  Nature       Date:  2011-10-02       Impact factor: 49.962

9.  Bimodal high-affinity association of Brd4 with murine leukemia virus integrase and mononucleosomes.

Authors:  Ross C Larue; Matthew R Plumb; Brandon L Crowe; Nikoloz Shkriabai; Amit Sharma; Julia DiFiore; Nirav Malani; Sriram S Aiyer; Monica J Roth; Frederic D Bushman; Mark P Foster; Mamuka Kvaratskhelia
Journal:  Nucleic Acids Res       Date:  2014-02-11       Impact factor: 16.971

10.  Bromodomain protein BRD4 is required for estrogen receptor-dependent enhancer activation and gene transcription.

Authors:  Sankari Nagarajan; Tareq Hossan; Malik Alawi; Zeynab Najafova; Daniela Indenbirken; Upasana Bedi; Hanna Taipaleenmäki; Isabel Ben-Batalla; Marina Scheller; Sonja Loges; Stefan Knapp; Eric Hesse; Cheng-Ming Chiang; Adam Grundhoff; Steven A Johnsen
Journal:  Cell Rep       Date:  2014-07-10       Impact factor: 9.423
View more
  37 in total

1.  Vitamin C Sensitizes Melanoma to BET Inhibitors.

Authors:  Sushmita Mustafi; Vladimir Camarena; Claude-Henry Volmar; Tyler C Huff; David W Sant; Shaun P Brothers; Zhao-Jun Liu; Claes Wahlestedt; Gaofeng Wang
Journal:  Cancer Res       Date:  2017-11-27       Impact factor: 12.701

2.  Pharmacokinetics-Driven Optimization of 7-Methylimidazo[1,5-a]pyrazin-8(7H)-one as Novel BRD4 Inhibitors.

Authors:  Yifei Yang; Pan Chen; Leilei Zhao; Fangqing Zhang; Huibin Zhang; Jinpei Zhou
Journal:  ACS Med Chem Lett       Date:  2019-11-26       Impact factor: 4.345

3.  The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma.

Authors:  A Esteve-Arenys; J G Valero; A Chamorro-Jorganes; D Gonzalez; V Rodriguez; I Dlouhy; I Salaverria; E Campo; D Colomer; A Martinez; G Rymkiewicz; P Pérez-Galán; A Lopez-Guillermo; G Roué
Journal:  Oncogene       Date:  2018-01-22       Impact factor: 9.867

4.  BRD4 orchestrates genome folding to promote neural crest differentiation.

Authors:  Ricardo Linares-Saldana; Wonho Kim; Nikhita A Bolar; Haoyue Zhang; Bailey A Koch-Bojalad; Sora Yoon; Parisha P Shah; Ashley Karnay; Daniel S Park; Jennifer M Luppino; Son C Nguyen; Arun Padmanabhan; Cheryl L Smith; Andrey Poleshko; Qiaohong Wang; Li Li; Deepak Srivastava; Golnaz Vahedi; Gwang Hyeon Eom; Gerd A Blobel; Eric F Joyce; Rajan Jain
Journal:  Nat Genet       Date:  2021-10-05       Impact factor: 38.330

5.  Selective Inhibition of Bromodomain-Containing Protein 4 Reduces Myofibroblast Transdifferentiation and Pulmonary Fibrosis.

Authors:  Ksenija Bernau; Melissa Skibba; Jonathan P Leet; Sierra Furey; Carson Gehl; Yi Li; Jia Zhou; Nathan Sandbo; Allan R Brasier
Journal:  Front Mol Med       Date:  2022-03-15

Review 6.  Involvement of Brd4 in different steps of the papillomavirus life cycle.

Authors:  Thomas Iftner; Juliane Haedicke-Jarboui; Shwu-Yuan Wu; Cheng-Ming Chiang
Journal:  Virus Res       Date:  2016-12-10       Impact factor: 3.303

7.  The epigenetic reader Brd4 is required for osteoblast differentiation.

Authors:  Christopher R Paradise; M Lizeth Galvan; Eva Kubrova; Sierra Bowden; Esther Liu; Mason F Carstens; Roman Thaler; Gary S Stein; Andre J van Wijnen; Amel Dudakovic
Journal:  J Cell Physiol       Date:  2019-12-23       Impact factor: 6.384

8.  Plk1 Inhibition Enhances the Efficacy of BET Epigenetic Reader Blockade in Castration-Resistant Prostate Cancer.

Authors:  Fengyi Mao; Jie Li; Qian Luo; Ruixin Wang; Yifan Kong; Colin Carlock; Zian Liu; Bennet D Elzey; Xiaoqi Liu
Journal:  Mol Cancer Ther       Date:  2018-05-01       Impact factor: 6.261

Review 9.  BET bromodomains as novel epigenetic targets for brain health and disease.

Authors:  Mandakini B Singh; Gregory C Sartor
Journal:  Neuropharmacology       Date:  2020-09-15       Impact factor: 5.250

10.  FOSL1 promotes metastasis of head and neck squamous cell carcinoma through super-enhancer-driven transcription program.

Authors:  Ming Zhang; Rosalie G Hoyle; Zhikun Ma; Bo Sun; Weixin Cai; Hongshi Cai; Nan Xie; Yadong Zhang; Jinsong Hou; Xiqiang Liu; Demeng Chen; Glen E Kellogg; Hisashi Harada; Yue Sun; Cheng Wang; Jiong Li
Journal:  Mol Ther       Date:  2021-03-29       Impact factor: 12.910
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.